CPSF1 and prostate carcinoma: To test if coordinate effects of CPSF1 knockdown on multiple genes in the glycolysis pathway may explain the selective inhibition of prostate cancer cell growth, we treated LNCaP95 and RWPE-1 cells with the aldolase inhibitor aldometanib47 and the PGK1 inhibitor CBR-470-1.48 LNCaP95 and RWPE-1 cell lines displayed similar sensitivity to growth inhibition by these inhibitors when they were tested as single agents (Figures S6B–S6E).